Christopher Asquith studied at the University of Southampton, U.K. to obtain a BSc in Chemistry and MSc in Chemistry. During this time, he worked for Prof. A. Ganesan on working on novel asthma targets and epigenetic prostate cancers modulators, this included a 3 month placement abroad at the University of Eastern Finland. He then moved to University College London, for his Ph.D. in Medicinal Chemistry working for Dr. S. Hilton. While completing his Ph.D., he worked in close international collaboration with the University of Zurich, Zurich, Switzerland and Zelinsky Institute, Moscow, Russia, investigating novel heterocyclic motifs against the zinc fingers of FIV/HIV. Asquith continued his interest in innovative ring systems with a short stay at the University of Cyprus, Cyprus working with Prof. P. Koutentis before joining the Structural Genomics Consortium at the University of North Carolina at Chapel Hill, working on chemical probe development for kinases with Prof. T. Willson. Subsequent to this Asquith moved to the School of Pharmacology to work as the lead medicinal chemist on the Illuminating the Druggable Genome (IDG) kinase program working with Prof. G Johnson.